172 related articles for article (PubMed ID: 31241440)
1. Overcoming Cancer Cell Drug Resistance by a Folic Acid Targeted Polymeric Conjugate of Buthionine Sulfoximine.
Cilurzo F; Cristiano MC; Da Pian M; Cianflone E; Quintieri L; Paolino D; Pasut G
Anticancer Agents Med Chem; 2019; 19(12):1513-1522. PubMed ID: 31241440
[TBL] [Abstract][Full Text] [Related]
2. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid.
Pasut G; Canal F; Dalla Via L; Arpicco S; Veronese FM; Schiavon O
J Control Release; 2008 May; 127(3):239-48. PubMed ID: 18346806
[TBL] [Abstract][Full Text] [Related]
3. Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.
Lewis-Wambi JS; Kim HR; Wambi C; Patel R; Pyle JR; Klein-Szanto AJ; Jordan VC
Breast Cancer Res; 2008; 10(6):R104. PubMed ID: 19061505
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine-loaded Folic Acid Tagged Liposomes: Improved Pharmacokinetic and Biodistribution Profile.
Unnam S; Panduragaiah VM; Sidramappa MA; Muddana Eswara BR
Curr Drug Deliv; 2019; 16(2):111-122. PubMed ID: 30360740
[TBL] [Abstract][Full Text] [Related]
5. Macromolecular bipill of gemcitabine and methotrexate facilitates tumor-specific dual drug therapy with higher benefit-to-risk ratio.
Das M; Jain R; Agrawal AK; Thanki K; Jain S
Bioconjug Chem; 2014 Mar; 25(3):501-9. PubMed ID: 24506698
[TBL] [Abstract][Full Text] [Related]
6. Glutathione depletion by buthionine sulfoximine induces DNA deletions in mice.
Reliene R; Schiestl RH
Carcinogenesis; 2006 Feb; 27(2):240-4. PubMed ID: 16162646
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effect of buthionine sulfoximine on the chlorin e6-based photodynamic treatment of cancer cells.
Lee HM; Kim DH; Lee HL; Cha B; Kang DH; Jeong YI
Arch Pharm Res; 2019 Nov; 42(11):990-999. PubMed ID: 31482490
[TBL] [Abstract][Full Text] [Related]
8. Development and evaluation of folate functionalized albumin nanoparticles for targeted delivery of gemcitabine.
Dubey RD; Alam N; Saneja A; Khare V; Kumar A; Vaidh S; Mahajan G; Sharma PR; Singh SK; Mondhe DM; Gupta PN
Int J Pharm; 2015 Aug; 492(1-2):80-91. PubMed ID: 26165611
[TBL] [Abstract][Full Text] [Related]
9. MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells.
Gana CC; Hanssen KM; Yu DMT; Flemming CL; Wheatley MS; Conseil G; Cole SPC; Norris MD; Haber M; Fletcher JI
Biochem Pharmacol; 2019 Oct; 168():237-248. PubMed ID: 31302132
[TBL] [Abstract][Full Text] [Related]
10. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
Mistry P; Loh SY; Kelland LR; Harrap KR
Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583
[TBL] [Abstract][Full Text] [Related]
11. Effect of 2-methoxyestradiol, buthionine sulfoximine and hydrogen peroxide on the viability of renal carcinoma cell lines (ACHN and ACVB).
Hirai Y; Kawabe N; Tsuda Y; Miyamoto S; Iwakawa S
Biol Pharm Bull; 2006 May; 29(5):1064-7. PubMed ID: 16651749
[TBL] [Abstract][Full Text] [Related]
12. Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma.
Fruehauf JP; Zonis S; al-Bassam M; Kyshtoobayeva A; Dasgupta C; Milovanovic T; Parker RJ; Buzaid AC
Chem Biol Interact; 1998 Apr; 111-112():277-305. PubMed ID: 9679561
[TBL] [Abstract][Full Text] [Related]
13. Nrf2 mediates the resistance of human A549 and HepG2 cancer cells to boningmycin, a new antitumor antibiotic, in vitro through regulation of glutathione levels.
Zhang HX; Chen Y; Xu R; He QY
Acta Pharmacol Sin; 2018 Oct; 39(10):1661-1669. PubMed ID: 30287928
[TBL] [Abstract][Full Text] [Related]
14. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
[TBL] [Abstract][Full Text] [Related]
15. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine.
Maeda H; Hori S; Ohizumi H; Segawa T; Kakehi Y; Ogawa O; Kakizuka A
Cell Death Differ; 2004 Jul; 11(7):737-46. PubMed ID: 15002036
[TBL] [Abstract][Full Text] [Related]
16. Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase.
Fruehauf JP; Zonis S; al-Bassam M; Kyshtoobayeva A; Dasgupta C; Milovanovic T; Parker RJ; Buzaid AC
Pigment Cell Res; 1997 Aug; 10(4):236-49. PubMed ID: 9263331
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo comparison between the effects of treatment with adenosine triphosphate and treatment with buthionine sulfoximine on chemosensitization and tumour growth of B16 melanoma.
Palomares T; Bilbao P; del Olmo M; Castro B; Calle Y; Alonso-Varona A
Melanoma Res; 1999 Jun; 9(3):233-42. PubMed ID: 10465578
[TBL] [Abstract][Full Text] [Related]
18. A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms.
Alexander RL; Greene BT; Torti SV; Kucera GL
Cancer Chemother Pharmacol; 2005 Jul; 56(1):15-21. PubMed ID: 15789226
[TBL] [Abstract][Full Text] [Related]
19. PKCĪ“ sensitizes neuroblastoma cells to L-buthionine-sulfoximine and etoposide inducing reactive oxygen species overproduction and DNA damage.
Marengo B; De Ciucis C; Ricciarelli R; Passalacqua M; Nitti M; Zingg JM; Marinari UM; Pronzato MA; Domenicotti C
PLoS One; 2011 Feb; 6(2):e14661. PubMed ID: 21326872
[TBL] [Abstract][Full Text] [Related]
20. Utilization of 6-(methylsulfinyl)hexyl isothiocyanate for sensitization of tumor cells to antitumor agents in combination therapies.
Yamaguchi H; Kidachi Y; Kamiie K; Noshita T; Umetsu H; Fuke Y; Ryoyama K
Biochem Pharmacol; 2013 Aug; 86(4):458-68. PubMed ID: 23791871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
